No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 51.300
- -0.720-1.38%
Close Jul 2 16:00 ET
- 51.500
- +0.200+0.39%
Post 17:50 ET
6.53BMarket Cap21.29P/E (TTM)
52.110High50.680Low1.04MVolume51.950Open52.020Pre Close53.29MTurnover0.83%Turnover Ratio24.43P/E (Static)127.27MShares53.22052wk High36.72P/B6.46BFloat Cap32.83052wk Low--Dividend TTM125.92MShs Float59.460Historical High--Div YieldTTM2.75%Amplitude1.410Historical Low51.252Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 520.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 28, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 28, with a total market value of approximately $520.4K
Halozyme Therapeutics(HALO.US) Officer Sells US$1.56 Million in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBrosse Nicole sold 30,000 shares of common stock on Jun 26, 27, 28, 2024 at an average price of $51.931 for a total value of $1.56 million.Source: Announceme
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 519.34K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 27, with a total market value of approximately $519.34
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 518.2K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 26, $Halozyme Therapeutics(HALO.US)$ Officer NICOLE LABROSSE intends to sell 10,000 shares of its common stock on Jun 26, with a total market value of approximately $518.2K
Halozyme Therapeutics Is Maintained at Buy by Benchmark
Halozyme Therapeutics Is Maintained at Buy by Benchmark
Benchmark Co. Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $60
Benchmark Co. analyst Robert Wasserman maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and adjusts the target price from $50 to $60.According to TipRanks data, the analyst has a success
Comments
Clinical Updates💉
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
4
EPS growth outshines yearly share price gain, hinting at cautious market sentiment. Despite recent sell-off, long-term investors see 16% annual return over five years, suggesting sell-off may be an opportunity for those seeking long-term growth.
The insider stock selling at Halozyme Therapeutics could raise concerns among shareholders. However, the fact that insiders maintain a considerable amount of shares might suggest some level of alignment between management and smaller shareholders.
Confidence in Halozyme Therapeutics is suggested due to solid EPS growth and significant insider investment aligning with shareholders' interests.
Gapping up
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
11
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg